The clinical value of minimal invasive autopsy in COVID-19 patients

Valentino D'Onofrio, Elena Donders, Marie-Elena Vanden Abeele, Jasperina Dubois, Reinoud Cartuyvels, Ruth Achten, Martin Lammens, Amelie Dendooven, Ann Driessen, Lukasz Augsburg, Jan Vanrusselt, Janneke Cox, Valentino D'Onofrio, Elena Donders, Marie-Elena Vanden Abeele, Jasperina Dubois, Reinoud Cartuyvels, Ruth Achten, Martin Lammens, Amelie Dendooven, Ann Driessen, Lukasz Augsburg, Jan Vanrusselt, Janneke Cox

Abstract

Background: Minimally invasive autopsy (MIA) is a validated and safe method to establish the cause of death (COD), mainly in low-resource settings. However, the additional clinical value of MIA in Coronavirus disease (COVID-19) patients in a high-resource setting is unknown. The objective was to assess if and how MIA changed clinical COD and contributing diagnoses in deceased COVID-19 patients.

Methods and findings: A prospective observational cohort from April to May 2020 in a 981-bed teaching hospital in the epicenter of the COVID-19 pandemic in Belgium was established. Patients who died with either PCR-confirmed or radiologically confirmed COVID-19 infection were consecutively included. MIA consisted of whole-body CT and CT-guided Tru-Cut® biopsies. Diagnostic modalities were clinical chart review, radiology, microbiology, and histopathology which were assessed by two independent experts per modality. MIA COD and contributing diagnoses were established during a multi-disciplinary meeting. Clinical COD (CCOD) and contributing diagnosis were abstracted from the discharge letter. The main outcomes were alterations in CCOD and contributing diagnoses after MIA, and the contribution of each diagnostic modality. We included 18 patients, of which 7 after intensive care unit hospitalization. MIA led to an alteration in 15/18 (83%) patients. The CCOD was altered in 5/18 (28%) patients. MIA found a new COD (1/5), a more specific COD (1/5), a less certain COD (1/5), or a contributing diagnosis to be the COD (2/5). Contributing diagnoses were altered in 14/18 (78%) patients: 9 new diagnoses, 5 diagnoses dismissed, 3 made more specific, and 2 made less certain. Overall, histopathology contributed in 14/15 (93%) patients with alterations, radiology and microbiology each in 6/15 (40%), and clinical review in 3/15 (20%). Histopathology was deemed the most important modality in 10 patients, radiology in two patients, and microbiology in one patient.

Conclusion: MIA, especially histological examination, can add valuable new clinical information regarding the cause of death in COVID-19 patients, even in a high-resource setting with wide access to premortem diagnostic modalities. MIA may provide important clinical insights and should be applied in the current ongoing pandemic.

Trial registration: Clinicaltrials.gov identifier: NCT04366882.

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Castillo P, Martínez MJ, Ussene E, Jordao D, Lovane L, Ismail MR, et al. Validity of a Minimally Invasive Autopsy for Cause of Death Determination in Adults in Mozambique: An Observational Study. PLoS Med. 2016;13(11):e1002171 10.1371/journal.pmed.1002171
    1. Rakislova N IM, Martinez A, et al. Minimally Invasive Autopsy: a more feasible and safer alternative to conventional autopsy in the COVID-19 pandemic era?. Med Clin Sci. 2020, 2(3):1–5.
    1. Hanley B, Lucas SB, Youd E, Swift B, Osborn M. Autopsy in suspected COVID-19 cases. J Clin Pathol. 2020;73(5):239–42. 10.1136/jclinpath-2020-206522
    1. Sciensano. Chronologie case definition document.
    1. Control ECfD. Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020. 2020.
    1. World Health O. WHO COVID-19 case definition Geneva: World Health Organization; 2020. 2020. Contract No.: WHO/2019-nCoV/Surveillance_Case_Definition/2020.1.
    1. Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, et al. Performance of Radiologists in Differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at Chest CT. Radiology. 2020;296(2):E46–e54.
    1. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. The Lancet Infectious Diseases.
    1. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020. 10.1016/j.jinf.2020.05.046
    1. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020. 10.1093/cid/ciaa530
    1. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clinical Microbiology and Infection.
    1. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148–50. 10.1016/j.thromres.2020.04.041
    1. Stessel B, Vanvuchelen C, Bruckers L, Geebelen L, Callebaut I, Vandenbrande J, et al. Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study. Thrombosis Research. 2020;194:209–15. 10.1016/j.thromres.2020.07.038
    1. Blokker BM, Weustink AC, Hunink MGM, Oosterhuis JW. Autopsy rates in the Netherlands: 35 years of decline. PLoS One. 2017;12(6):e0178200 10.1371/journal.pone.0178200
    1. The Royal College of Pathologists. Autopsy practice relating to possible cases of COVID-19 (2019-nCov ncfChwrod-p.
    1. Yaacoub S, Schünemann HJ, Khabsa J, El-Harakeh A, Khamis AM, Chamseddine F, et al. Safe management of bodies of deceased persons with suspected or confirmed COVID-19: a rapid systematic review. BMJ Glob Health. 2020;5(5). 10.1136/bmjgh-2020-002650
    1. Vincent JL, Taccone FS. Understanding pathways to death in patients with COVID-19. Lancet Respir Med. 2020;8(5):430–2.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe